Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation
Retinal disease: How anti-diabetic drug can help eyes Pathological retinal angiogenesis, the damaging formation of new blood vessels in the retina, which is associated with various diseases including diabetes, could be reduced using the anti-diabetic drug evogliptin to inhibit the effects of a vascu...
Main Authors: | Songyi Seo, Mi-Kyung Kim, Ryul-I Kim, Yeongju Yeo, Koung Li Kim, Wonhee Suh |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-10-01
|
Series: | Experimental and Molecular Medicine |
Online Access: | https://doi.org/10.1038/s12276-020-00512-8 |
Similar Items
-
Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
by: Mi-Jin Kim, et al.
Published: (2020-02-01) -
Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
by: Rhee SJ, et al.
Published: (2016-08-01) -
Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
by: Gu N, et al.
Published: (2014-10-01) -
Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice.
by: Yu-Na Chae, et al.
Published: (2015-01-01) -
Efficacy and safety of novel dipeptidyl-peptidase-4 inhibitor evogliptin in the management of type 2 diabetes mellitus: A meta-analysis
by: Deep Dutta, et al.
Published: (2020-01-01)